Clopidogrel
Product Images NDC 68071-2813

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-2813). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2813 9)

Label for Clopidogrel 75mg tablets by NuCare Pharmaceuticals, Inc., displaying NDC 68071-2813-9 and package quantity of 90 tablets. Each film-coated tablet contains 97.875mg of Clopidogrel Bisulfate, equivalent to 75mg of Clopidogrel base. Includes manufacturing and packaging details, prescription warning, and storage instructions at controlled temperature 68-77°F.*

FDA Label Image

Figure (Clopidogrel Fig1)

A line graph depicting cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two comparison lines represent Aspirin and Clopidogrel Bisulfate, showing similar event rates over time with a p-value of 0.045 indicated on the chart.*

FDA Label Image

Figure (Clopidogrel Fig2)

A line graph comparing cumulative event rates (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke in patients receiving placebo plus aspirin versus clopidogrel bisulfate plus aspirin. The graph shows lower event rates in the clopidogrel bisulfate group with a statistically significant difference (P=0.00009).*

FDA Label Image

Figure (Clopidogrel Fig3)

A data table presenting subgroup analysis of Clopidogrel Bisulfate versus placebo with hazard ratios and 95% confidence intervals. Subgroups include age, gender, race, enzyme elevation, diabetes status, previous myocardial infarction and stroke, use of Heparin/LMWH, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The table shows the number and percentage of events in each group along with a graphical hazard ratio plot.*

FDA Label Image

Figure (Clopidogrel Fig4)

A survival curve chart showing the percentage of deaths before first discharge over 28 days since randomization, comparing Clopidogrel with placebo. The y-axis represents the percentage dead, while the x-axis shows days up to 28. The chart indicates a 7% proportional risk reduction with Clopidogrel compared to placebo.*

FDA Label Image

Figure (Clopidogrel Fig5)

A Kaplan-Meier plot showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph compares events in patients receiving placebo (10.1%) versus clopidogrel (9.2%), indicating a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

Figure (Clopidogrel Fig6)

Data table showing subgroup analysis comparing Clopidogrel bisulfate versus placebo, reporting participant counts (N) and event percentages across various demographics and clinical characteristics such as gender, age, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent use. The right side presents a forest plot of odds ratios with 99% confidence intervals depicting the efficacy comparison of Clopidogrel versus placebo.*

FDA Label Image

Change Relative To Clopidogrel Bisulfate Administered Alone (Clopidogrel Fig8)

A horizontal bar chart illustrating the effect of co-administered proton pump inhibitors (dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, omeprazole 80 mg) on the active metabolite AUC. The chart shows mean values with 90% confidence intervals, with values ranging approximately from 0.4 to 1.4 on the x-axis, indicating the impact of each drug on the metabolite's exposure.*

FDA Label Image

Figure (Clopidogrel Fig9)

A forest plot chart comparing Clopidogrel Bisulfate and Aspirin outcomes across qualifying conditions including Stroke, MI, PAD, and Overall. It displays sample sizes, event counts with percentages, and hazard ratios with 95% confidence intervals for each condition, indicating which treatment is favored.*

FDA Label Image

Clopidogrel-str (Clopidogrel Str)

Chemical structure of clopidogrel sulfate, showing the molecular arrangement including a thiophene ring, a chlorophenyl group, and the sulfate component as indicated by H2SO4.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.